Use of Clinically Available PPAR Agonists for Heart Failure; Do the Risks Outweigh the Potential Benefits?

E-ISSN： 1874-4702|5|2|255-263

ISSN： 1874-4672

Source： Current Molecular Pharmacology, Vol.5, Iss.2, 2012-06, pp. : 255-263

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?

By Murray T Jock

Expert Opinion on Drug Safety, Vol. 5, Iss. 2, 2006-03 ,pp. : 265-274

Informa Healthcare

Access to resources Recommend Favorite

Fluoxetine – do the benefits outweigh the risks in adolescent major depression?

By Doggrell Sheila A

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 1, 2005-01 ,pp. : 147-150

Informa Healthcare

Access to resources Recommend Favorite

Iodine Supplementation: Benefits Outweigh Risks

By Delange F.

Drug Safety, Vol. 22, Iss. 2, 2000-02 ,pp. : 89-95

Adis International

Access to resources Recommend Favorite

Risk of Melanoma with Psoralen/Ultraviolet A Therapy for Psoriasis: Do the Known Risks Now Outweigh the Benefits?

By Lindelöf B.

Drug Safety, Vol. 20, Iss. 4, 1999-04 ,pp. : 289-297

Adis International

Access to resources Recommend Favorite

Newer Biological Agents in the Treatment of Rheumatoid Arthritis: Do the Benefits Outweigh the Risks?

By Nurmohamed Michael T.

Drugs, Vol. 69, Iss. 15, 2009-10 ,pp. : 2035-2043

Adis International

Access to resources Recommend Favorite